Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3008356 in Healthy and Obese Subjects
NCT02742766Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BOS-356 in obesity and Nonalcoholic steatohepatitis (NASH) (6 arms), sponsored by GSK. Primary endpoints: Number of Participants With Abnormal Findings in Physical Examinations, Number of Participants With Vital Signs of Potential Clinical Concern and 4 more. Started Mar 2016; status: completed.
02
Drugs
BOS-356
03
Conditions
obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02742766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742766.